Latest Conference Coverage

Paula E. Voinescu, MD, PhD: Seizure Frequency in Pregnancy, Postpartum

The attending neurologist at Brigham and Women's Hospital spoke about how seizure frequency during pregnancy and postpartum varies by epilepsy type.

Laura Julian, PhD: The Floodlight Open MS Database

The principal medical science director at Genentech spoke about the decisions behind the tools being used for measurement, and what the neurologists can get from the data.

Starting, Stopping Antiepileptic Medications in Acute Symptomatic Seizures

The Director of the cEEG and Epilepsy Consult Service at the Cleveland Clinic Epilepsy Center spoke about when clinicians should initiate and stop anti-seizure medications.

Stephen Hantus, MD: Acute Symptomatic Seizures

The Director of the cEEG and Epilepsy Consult Service at the Cleveland Clinic Epilepsy Center spoke about the cautious for physicians treating patients with acute symptomatic seizures.

Trevor Resnick, MD, on Perampanel for Secondarily Generalized Seizures

The pediatric epileptologist at Nicklaus Children’s Hospital spoke about the long-term seizure freedom data that showed that perampanel was associated with a sustained or increased improvement in seizure control.

Uri Kramer, MD: Treating Epilepsy With Cannabis

The professor of pediatrics at Tel Aviv University explained what has been fleshed out by the research and shared his opinion on cannabidiol’s use.

Christos Papadelis, PhD: The HOPE Project in Epilepsy

The head of the Children’s Brain Dynamics Laboratory at Boston Children’s Hospital discussed the HOPE project and its goals moving forward.

Jeffrey Buchhalter, MD: Disclosing SUDEP Risk to Patients With Epilepsy

The pediatric epileptologist and adjunct professor of pediatrics at the University of Calgary spoke about how drastically things have changed surrounding the patient-physician conversation about SUDEP.

Imad Najm, MD: Deep Brain Stimulation and Selection Criteria for Patients with Epilepsy

The Director of the Cleveland Clinic Epilepsy Center spoke about how important it is for clinicians to not select the wrong patients for deep brain stimulation.

Using Big Data to Personalize Epilepsy Care

The professor and head of the Department of Neurology and Rehabilitation at the University of Illinois at Chicago spoke about how data can better inform epilepsy care.

Kate Davis, MD, MSTR: Increasing Treatment Options for Epilepsy Patients

The epileptologist at the University of Pennsylvania spoke about the multiple options for patients with epilepsy and the need for a better understanding of choosing from the options.

Imad Najm, MD: Deep Brain Stimulation and Epilepsy

The director of the epilepsy center at Cleveland Clinic spoke about the process that leads to the selection of candidacy for deep brain stimulation.

Should More Physicians be Screening Teens With Epilepsy for Depression?

The director of the Epilepsy Center at Children's Health spoke about the findings of the clinical screening program, and how depression is often overlooked in patients with epilepsy.

Cenobamate Shows Promise, Reduces Frequency of Partial-Onset Seizures

The chief medical officer at SK Life Science discussed what makes cenobamate unique, as well as what current studies have discovered.

Hillary Thomas, PhD: Screening Patients With Epilepsy for Depression

The pediatric psychologist at Children’s Medical Center discussed what her team does to assess patients in the clinic when something comes up as a result of a patient’s screening.

Joseph Sirven, MD: Variables Impacting Vehicle Use for Patients with Epilepsy

The Director of the Epilepsy Division at Mayo Clinic in Phoenix discussed the issue of driving when withdrawing patients off seizure medication either because of treatment, remission or surgical intervention.

Anup D. Patel, MD: CBD Increasing Treatment Options

The section chief of pediatric neurology at Nationwide Children’s Hospital discussed cannabidiol's potential in the Lennox-Gastaut syndrome space.

Robert S. Fisher, MD, PhD: Exploring Unanswered Questions in Epilepsy

The Director of the Stanford Epilepsy Center discussed the work that’s left to be done in the field of epilepsy.

Daniel M. Goldenholz, MD, PhD: Assessing the Risk for SUDEP

The instructor in neurology at Beth Israel Deaconess Medical Center spoke about what clinicians can do right now to mitigate the risk of SUDEP and the myriad of options for them to utilize.

Dan Barber, MBA: Advantages of Diazepam Buccal Soluble Film Formulation

The SVP and chief strategy and development officer at Aquestive Therapeutics discussed the hope to provide both patients and providers with a more favorable, and still efficacious, option for seizure clusters.

Low-Dose, Slow-Titrated Cenobamate Shows No Incidence of DRESS Syndrome

Recent data has shown that a start low, go slow approach with cenobamate may mitigate the risk of drug reaction with eosinophilia and systemic symptoms syndrome.

Jerome Engel, Jr., MD, PhD on Referring Patients to Epilepsy Centers

The Director of the UCLA Seizure Disorder Center explained the importance of referring patients with seizures to epilepsy centers.

NeuroPace RNS System Shows Improvements Over 9-Year Period

The largest and longest prospective neuromodulation trial in the field of epilepsy showed about a 75% response rate with patients achieving at least a 50% reduction in seizures.

Robert S. Fisher, MD, PhD: What Will an Epilepsy Physician Be Doing in the Future?

The Director of the Stanford Epilepsy Center discussed the current activities of epileptologists and considered how this might change in the near future, given advancing technology.

Lynn Liu, MD: When Should We Measure Antiepileptic Blood Levels?

The associate professor of neurology at the University of Rochester shared some of her advice for treating patients with epilepsy and focusing on the patient.

Does CBD's Approval Mark a Turning Point for Treatments in Dravet Syndrome?

The director of the Epilepsy Program at Children’s Hospital of Philadelphia spoke about the long-awaited advancement brought on by cannabidiol for Dravet syndrome.

Diazepam Buccal Soluble Film Formulation Shows Comparable Exposure Across Seizure Periods

This novel dosage form of diazepam had comparable times to maximal concentration in both 2-hour and 4-hour timeframes.

Anup D. Patel, MD: Long-Term Use of CBD in Lennox-Gastaut Syndrome

The section chief of pediatric neurology at Nationwide Children’s Hospital and an associate professor of clinical pediatrics and neurology at The Ohio State University College of Medicine spoke about what the findings mean for patients.

CBD Shows Continued Safety Profile, Seizure Reductions in Open-Label Extension

The recently approved therapy remained generally well tolerated and improvements in overall condition in Subject/Caregiver Global Impression of Change scores.

Phenotyping as a Rational for Drug Development in Obstructive Sleep Apnea

The Professor of Medicine at the University of New South Wales highlighted the latest knowledge in sleep apnea phenotyping and its crucial role in the development of targeted pharmacotherapies to treat OSA.